Authors | Study Type | Year of Publication | Recruitment period | Median age (SD) | Patients with WTLM | Concurrent pulmonary M | Outcome of WTLM Patients | Group A: LR | Outcome group A | Group B: no LR | Outcome group B |
---|---|---|---|---|---|---|---|---|---|---|---|
Filler et al. | CS | 1969 | 1963-1968 | 4.4y | 2 sync: 0 meta: 2 | 1/2 (50%) | Survival in 2/2 (100%) | 2 | Survival in 2/2 (100%) | 0 | - |
Foster | CS | 1978 | 1947-1978 | - | 15 Sync: X meta: 2+X | Unclear | Survival in 10/15 (67%) | 15 | Survival in 10/15 (67%) | 0 | - |
Edwards et al. | CS | 1990 | 1978-1987 | 10y | 1 sync: 0 meta: 1 | 0/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Rao et al. | CR | 1992 | - | 8y | 1 sync: 0 meta: 1 | 0/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Goering et al. | CR | 2002 | - | - | 1 sync: 0 meta: 1 | Unclear | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Patel et al. | CR | 2003 | - | 0.8y | 1 sync: 0 meta: 1 | 0/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Su et al. | ROS-SC | 2007 | 1988 - 2005 | 6.2y (7.1) | 3 sync: 1 meta: 2 | 1/3 (33%) | Survival in 0/3 (0%) | 3 | Survival in 0/3 (0%) | 0 | - |
Fuchs et al. | ROS-OncReg | 2008 | 1994-2004 | 6.5y (8.6) | 45 sync: 29 meta: 16 | 28/45 (62%) | Survival in 24/45 (53%) | 21 | Survival in 12/21 (57%) | 24 | Survival in 12/24 (50%) |
Ehrlich et al. | ROS-OncReg | 2009 | 1986-2002 | - | 96 sync: 96 meta: 0 | 62/96 (65%) | - | 25 | 5-year EFS 86%* | 71 | 5-year EFS 68%* |
Dressler et al. | CR | 2010 | - | 9y | 1 sync: 0 meta: 1 | 1/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Aronson et al. | ROS-SC | 2012 | 2002-2010 | 3.8y (3.2) | 19 sync: 19 meta: 0 | 15/19 (79%) | 5-year OS 47% | 3 | unknown | 16 | unknown |
Berger et al. | ROS-MC | 2013 | 1994-2011 | 5.4y (4.2) | 6 sync: 6 meta: 0 | 3/6 (50%) | Survival in 3/6 (50%) | 2 | Survival in 2/2 (100%) | 4 | Survival in 1/4 (25%) |
Liné et al. | CS | 2014 | 1994-2001 | 1.9y (2.6) | 3 sync: 0 meta: 3 | Unclear | Survival in 2/3 (67%) | 3 | Survival 2/3 (67%) | 0 | - |
Liné et al. | ROS-OncReg | 2020 | 2002-2012 | 6y (2.6) | 18 sync: 18 meta: 0 | 14/18 (78%) | Survival in 16/18 (89%) | 14 | Survival in 12/14 (86%) | 4 | Survival in 4/4 (100%) |